{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:53:13Z","timestamp":1789854793643,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T00:00:00Z","timestamp":1442880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40259-015-0139-0","type":"journal-article","created":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T12:38:59Z","timestamp":1442925539000},"page":"353-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Bivalent rLP2086 Vaccine (Trumenba\u00ae): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10\u201325\u00a0Years"],"prefix":"10.1007","volume":"29","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohita","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"issue":"RR-2","key":"139_CR1","first-page":"1","volume":"62","author":"AC Cohn","year":"2013","unstructured":"Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1\u201328.","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"139_CR2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","volume":"50","author":"AC Cohn","year":"2010","unstructured":"Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184\u201391.","journal-title":"Clin Infect Dis"},{"issue":"18","key":"139_CR3","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","volume":"344","author":"NE Rosenstein","year":"2001","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001;344(18):1378\u201388.","journal-title":"N Engl J Med"},{"issue":"6","key":"139_CR4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307\u201326.","journal-title":"J Exp Med"},{"issue":"4403","key":"139_CR5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1126\/science.451601","volume":"205","author":"A Nicholson","year":"1979","unstructured":"Nicholson A, Lepow IH. Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science. 1979;205(4403):298\u20139.","journal-title":"Science"},{"issue":"Suppl 2","key":"139_CR6","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","volume":"30","author":"SA Halperin","year":"2012","unstructured":"Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26\u201336.","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"139_CR7","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","volume":"27","author":"LH Harrison","year":"2009","unstructured":"Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51\u201363.","journal-title":"Vaccine"},{"issue":"5","key":"139_CR8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","volume":"44","author":"P Boisier","year":"2007","unstructured":"Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44(5):657\u201363.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"139_CR9","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1365-3156.2012.03085.x","volume":"17","author":"R Borrow","year":"2012","unstructured":"Borrow R. Advances with vaccination against Neisseria meningitidis. Trop Med Int Health. 2012;17(12):1478\u201391.","journal-title":"Trop Med Int Health"},{"issue":"11","key":"139_CR10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-013-0079-2","volume":"73","author":"AC Cohn","year":"2013","unstructured":"Cohn AC, Harrison LH. Meningococcal vaccines: current issues and future strategies. Drugs. 2013;73(11):1147\u201355.","journal-title":"Drugs"},{"issue":"Suppl 2","key":"139_CR11","doi-asserted-by":"crossref","first-page":"B42","DOI":"10.1016\/j.vaccine.2009.05.001","volume":"27","author":"IM Feavers","year":"2009","unstructured":"Feavers IM, Pizza M. Meningococcal protein antigens and vaccines. Vaccine. 2009;27(Suppl 2):B42\u201350.","journal-title":"Vaccine"},{"issue":"5","key":"139_CR12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/erv.11.50","volume":"10","author":"AS Anderson","year":"2011","unstructured":"Anderson AS, Jansen KU, Eiden J. New frontiers in meningococcal vaccines. Expert Rev Vaccines. 2011;10(5):617\u201334.","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl 2","key":"139_CR13","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","volume":"27","author":"J Holst","year":"2009","unstructured":"Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3\u201312.","journal-title":"Vaccine"},{"issue":"4","key":"139_CR14","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","volume":"72","author":"LD Fletcher","year":"2004","unstructured":"Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088\u2013100.","journal-title":"Infect Immun"},{"issue":"6","key":"139_CR15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","volume":"197","author":"V Masignani","year":"2003","unstructured":"Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197(6):789\u201399.","journal-title":"J Exp Med"},{"issue":"1","key":"139_CR16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","volume":"177","author":"G Madico","year":"2006","unstructured":"Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177(1):501\u201310.","journal-title":"J Immunol"},{"issue":"Suppl 8","key":"139_CR17","doi-asserted-by":"crossref","first-page":"I46","DOI":"10.1016\/j.vaccine.2008.11.068","volume":"26","author":"M Pizza","year":"2008","unstructured":"Pizza M, Donnelly J, Rappuoli R. Factor H-binding protein, a unique meningococcal vaccine antigen. Vaccine. 2008;26(Suppl 8):I46\u20138.","journal-title":"Vaccine"},{"issue":"7240","key":"139_CR18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature07769","volume":"458","author":"MC Schneider","year":"2009","unstructured":"Schneider MC, Prosser BE, Caesar JJE, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009;458(7240):890\u20133.","journal-title":"Nature"},{"issue":"25\u20136","key":"139_CR19","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","volume":"27","author":"LK McNeil","year":"2009","unstructured":"McNeil LK, Murphy E, Zhao X-J, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 2009;27(25\u20136):3417\u201321.","journal-title":"Vaccine"},{"issue":"3","key":"139_CR20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","volume":"200","author":"E Murphy","year":"2009","unstructured":"Murphy E, Andrew L, Lee K-L, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200(3):379\u201389.","journal-title":"J Infect Dis"},{"issue":"29\u201330","key":"139_CR21","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","volume":"29","author":"X Wang","year":"2011","unstructured":"Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29\u201330):4739\u201344.","journal-title":"Vaccine"},{"issue":"37","key":"139_CR22","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","volume":"28","author":"H-Q Jiang","year":"2010","unstructured":"Jiang H-Q, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28(37):6086\u201393.","journal-title":"Vaccine"},{"issue":"1","key":"139_CR23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/hv.34293","volume":"11","author":"GW Zlotnick","year":"2015","unstructured":"Zlotnick GW, Jones TR, Liberator P, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease. Hum Vaccin Immunother. 2015;11(1):5\u201313.","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"139_CR24","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.vaccine.2009.12.027","volume":"28","author":"R Pajon","year":"2010","unstructured":"Pajon R, Beernink PT, Harrison LH, et al. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine. 2010;28(9):2122\u20139.","journal-title":"Vaccine"},{"issue":"9","key":"139_CR25","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1099\/mic.0.029876-0","volume":"155","author":"PT Beernink","year":"2009","unstructured":"Beernink PT, Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology. 2009;155(9):2873\u201383.","journal-title":"Microbiology"},{"key":"139_CR26","unstructured":"Pfizer. Trumenba\u00ae (meningococcal group B vaccine): US prescribing information. 2015. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=1796 . Accessed 01 Sept 2015."},{"key":"139_CR27","unstructured":"US FDA. Bexsero\u00ae (meningococcal group B vaccine): US prescribing information. 2015. http:\/\/www.fda.gov . Accessed 01 Sept 2015."},{"key":"139_CR28","unstructured":"US FDA. Clinical review\u2014Trumenba. 2014. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM424626.pdf . Accessed 01 Sept 2015."},{"key":"139_CR29","doi-asserted-by":"crossref","unstructured":"Vesikari T, Beeslaar J, Eiden J, et al. Safety, tolerability, and immunogenicity of an investigational meningococcal serogroup B bivalent rLP2086 vaccine in healthy adolescents aged 11\u201318\u00a0years in three phase 2, randomized, controlled studies [abstract no. 1082 plus poster]. IDWeek 2014, 8\u201312 Oct 2014, Philadelphia.","DOI":"10.1093\/ofid\/ofu052.790"},{"issue":"8","key":"139_CR30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","volume":"12","author":"PC Richmond","year":"2012","unstructured":"Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(8):597\u2013607.","journal-title":"Lancet Infect Dis"},{"key":"139_CR31","doi-asserted-by":"crossref","unstructured":"Vesikari T, \u00d8stergaard L, Diez-Domingo J, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc. 2015. doi: 10.1093\/jpids\/piv039 .","DOI":"10.1093\/jpids\/piv039"},{"issue":"7","key":"139_CR32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4161\/hv.19983","volume":"8","author":"EA Sheldon","year":"2012","unstructured":"Sheldon EA, Schwartz H, Jiang Q, et al. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother. 2012;8(7):888\u201395.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"139_CR33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","volume":"31","author":"HS Marshall","year":"2013","unstructured":"Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013;31(12):1569\u201375.","journal-title":"Vaccine"},{"issue":"10","key":"139_CR34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e31826327e4","volume":"31","author":"HS Marshall","year":"2012","unstructured":"Marshall HS, Richmond PC, Nissen MD, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18\u201336\u00a0months: a phase 1 randomized controlled clinical trial. Pediatr Infect Dis J. 2012;31(10):1061\u20138.","journal-title":"Pediatr Infect Dis J."},{"issue":"43","key":"139_CR35","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","volume":"30","author":"PC Richmond","year":"2012","unstructured":"Richmond PC, Nissen MD, Marshall HS, et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine. 2012;30(43):6163\u201374.","journal-title":"Vaccine"},{"issue":"4","key":"139_CR36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/INF.0b013e31827b0d24","volume":"32","author":"MD Nissen","year":"2013","unstructured":"Nissen MD, Marshall HS, Richmond PC, et al. A randomized, controlled, phase 1\/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J. 2013;32(4):364\u201371.","journal-title":"Pediatr Infect Dis J"},{"key":"139_CR37","unstructured":"US FDA. Gardasil (human papillomavirus quadrivalent vaccine): US prescribing information. 2015. http:\/\/www.fda.gov . Accessed 01 Sept 2015."},{"key":"139_CR38","unstructured":"Electronic Medicines Compendium. Repevax [diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine]: summary of product characteristics. 2012. http:\/\/www.medicines.org.uk\/emc . Accessed 01 Sept 2015."},{"key":"139_CR39","doi-asserted-by":"crossref","unstructured":"Bhuyan P, Eiden J, Jones TR, et al. Immunogenicity of human papilloma vaccine coadministered with an investigational bivalent rLP2086 vaccine against meningococcal serogroup B in healthy adolescents [abstract no. 1081 plus poster]. IDWeek 2014, 8\u201312 Oct 2014, Philadelphia.","DOI":"10.1093\/ofid\/ofu052.789"},{"key":"139_CR40","unstructured":"Vesikari T, Wysocki J, Kieninger D, et al. Randomized, placebo-controlled, phase 2 study of the immunogenicity and safety of Repevax\u00ae administered concomitantly with bivalent rLP2086 vaccine in healthy adolescents [abstract no. 179]. In: 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases. 2014."},{"issue":"24","key":"139_CR41","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","volume":"24","author":"R Borrow","year":"2006","unstructured":"Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization\u2014international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005. Vaccine. 2006;24(24):5093\u2013107.","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"139_CR42","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","volume":"27","author":"CE Frasch","year":"2009","unstructured":"Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27(Suppl 2):B112\u20136.","journal-title":"Vaccine"},{"key":"139_CR43","unstructured":"US FDA. Pharmacovigilance plan review\u2014Trumenba. 2014. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM424630.pdf . Accessed 01 Sept 2015."},{"key":"139_CR44","unstructured":"Pfizer. CDC Advisory Committee on Immunization Practices votes to recommend serogroup B meningococcal disease vaccination including Trumenba\u00ae for adolescents and young adults 16 through 23\u00a0years of age. 2015. http:\/\/www.pfizer.com\/news\/press-release . Accessed 01 Sept 2015."},{"issue":"22","key":"139_CR45","first-page":"608","volume":"64","author":"T Folaranmi","year":"2015","unstructured":"Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged \u226510\u00a0years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608\u201312.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"139_CR46","unstructured":"Centers for Disease Control and Prevention. Interim guidance for control of serogroup B meningococcal disease outbreaks in organizational settings. 2015. http:\/\/www.cdc.gov\/meningococcal\/downloads\/interim-guidance.pdf . Accessed 01 Sept 2015."},{"issue":"31","key":"139_CR47","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1016\/j.vaccine.2015.06.046","volume":"33","author":"E Oviedo-Orta","year":"2015","unstructured":"Oviedo-Orta E, Ahmed S, Rappuoli R, et al. Prevention and control of meningococcal outbreaks: the emerging role of serogroup B meningococcal vaccines. Vaccine. 2015;33(31):3628\u201335.","journal-title":"Vaccine"},{"issue":"22","key":"139_CR48","first-page":"606","volume":"64","author":"HM Soeters","year":"2015","unstructured":"Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college\u2014Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"139_CR49","unstructured":"Pfizer. Pfizer announces positive top-line results of a phase 2 study of TRUMENBA\u00ae (meningococcal group B vaccine) co-administered with routine meningococcal (A, C, Y, and W) and tetanus, diphtheria and pertussis (Tdap) vaccines in adolescents. 2015. http:\/\/www.pfizer.com\/news\/press-release . Accessed 01 Sept 2015."},{"key":"139_CR50","unstructured":"Pfizer. Pfizer announces positive topline results of two phase 3 studies of Trumenba\u00ae (meningococcal group B vaccine). 2015. http:\/\/www.pfizer.com\/news\/press-release . Accessed 01 Sept 2015."},{"issue":"48","key":"139_CR51","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1016\/j.vaccine.2010.09.038","volume":"28","author":"DAA Ala\u2019Aldeen","year":"2010","unstructured":"Ala\u2019Aldeen DAA, Flint M, Oldfield NJ, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine. 2010;28(48):7667\u201375.","journal-title":"Vaccine"},{"issue":"9","key":"139_CR52","doi-asserted-by":"crossref","first-page":"e107240","DOI":"10.1371\/journal.pone.0107240","volume":"9","author":"L Lem\u00e9e","year":"2014","unstructured":"Lem\u00e9e L, Hong E, Etienne M, et al. Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis. PLoS One. 2014;9(9):e107240.","journal-title":"PLoS One"},{"issue":"5","key":"139_CR53","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","volume":"197","author":"MCJ Maiden","year":"2008","unstructured":"Maiden MCJ, Ibarz-Pav\u00f3n AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737\u201343.","journal-title":"J Infect Dis"},{"key":"139_CR54","unstructured":"European Medicines Agency. Bexsero (meningococcal group B vaccine): summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 01 Sept 2015."},{"issue":"3","key":"139_CR55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4161\/hv.23222","volume":"9","author":"AS Anderson","year":"2013","unstructured":"Anderson AS, Hao L, Jiang Q, et al. Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease. Hum Vaccin Immunother. 2013;9(3):471\u20139.","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"139_CR56","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","volume":"199","author":"PT Beernink","year":"2009","unstructured":"Beernink PT, Caugant DA, Welsch JA, et al. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis. 2009;199(9):1360\u20138.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"139_CR57","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4161\/hv.7.0.14564","volume":"7","author":"SL Harris","year":"2011","unstructured":"Harris SL, Zhu D, Murphy E, et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease. Hum Vaccin. 2011;7(Suppl 1):68\u201374.","journal-title":"Hum Vaccin"},{"issue":"7","key":"139_CR58","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","volume":"31","author":"E Hong","year":"2013","unstructured":"Hong E, Giuliani MM, Deghmane A-E, et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine. 2013;31(7):1113\u20136.","journal-title":"Vaccine"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-015-0139-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-015-0139-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-015-0139-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T03:40:29Z","timestamp":1653190829000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-015-0139-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,22]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["139"],"URL":"https:\/\/doi.org\/10.1007\/s40259-015-0139-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,22]]}}}